L'evoluzione dell'ormonoterapia nelle attuali strategie di trattamento del carcinoma mammario

Howell A. : The UK experience with Faslodex®. Mini Symposium II: Selective Estrogen Receptor Modulators (SERMs). 21^st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1998.

DeFriend D.J. , Howell A. , Nicholson R.I. : Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54, 408–414.

Wakeling A.E. : The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993; 25, 1–9.

Buzdar A.U. , Jonat W. , Howell A. : Significant improved survival with Arimidex (anastrozole) vs megestrol acetate (MA) in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc Am Soc Clin Oncol 1997, A545.

Bonneterre J. , Thurlimann B.J.K. , Robertson J.F.R. : Preliminary results of a large comparative multicentre clinical trial comparing the efficacy and tolerability of Arimidex (anastrozole) and Tamoxifen (TAM) in postmenopausal women with advanced breast cancer (ABC). Proc ECCO 10: A1257, Sept 12-16, 1999, Vienna, Austria.

Pritchard K.I. : New approaches to advanced breast cancer. Proc ECCO 10 - Sept 12-16, 1999, Vienna, Austria.

Milla Santos A. , Milla L. , Rallo L. : Anastrozole vs tamoxifen in hormone-dependent advanced breast cancer. A phase II randomized trial. Breast Cancer Res Treat 2000; 64 (1): A173.

Burstein H.J. , Winer E. : Primary care for survivors of breast cancer. NEJM 2000; 343: 1086.

Boccardo F. , Rubagotti A. , Amoroso D. : Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Onc 2000; 18: 2718–2727.

Baum M. : Breast Cancer Res Treat 1999; 57: A24.

Kuter I. : Breast cancer highlights. Oncologist 1999; 4: 299–308.

Aebi S. , Gelber S. , Castiglione-Gertsch M. : Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869–1874.